VI
Viyash Scientific Ltd (VIYASH)
₹218.39
Mkt cap
₹9,648 Cr
P/E ratio
43.50
P/B
3.28
Div yield
0.00%
ROE
7.39%
ROCE
13.40%
EPS (TTM)
₹5.02
Book value
₹67
52W range
178–298
Sector
Healthcare
Price history
Previous close
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
NSE VIYASHBSE 512529
Health check
Mixed
ValuationFair
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−26.71% from high₹218
₹178+22.60% from low₹298
Current
₹218.39
Prev close
₹224.55
Day
−2.74%
Price performance
1D
−2.87%
1W
+6.82%
1M
−8.38%
3M
−13.42%
6M
+5.26%
1Y
+7.11%
YTD
+3.75%
Financials
Revenue, profit & margin
P/E ratio
43.5×
VIYASH is 26% above the sector median of 34.4×
VIYASH43.5×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 346 | 329 | 361 | 390 | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 | |
| Expenses | 341 | 331 | 307 | 329 | 348 | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 | |
| Operating Profit | -8 | 15 | 22 | 32 | 42 | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 | |
| OPM % | -2.5% | 4.4% | 7% | 9% | 11% | 11% | 13% | 12% | 15% | 20% | 20% | 20% | 19% | |
| Other Income | -23 | 10 | 7 | -1 | 3 | 0 | 4 | 1 | 6 | 6 | -27 | 16 | 8 | |
| Interest | 10 | 13 | 13 | 12 | 16 | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 | |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 | |
| Profit before tax | -56 | -3 | 1 | 3 | 12 | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 | |
| Tax % | -38% | 123% | -617% | 52% | 24% | 20% | -71% | 36% | 24% | 29% | 34% | 47% | 29% | |
| Net Profit | -35 | -7 | 11 | 1 | 9 | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 | |
| EPS in Rs | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.50% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26 |
| Earnings day | +0.50% |
| +1 day | +1.86% |
| +5 days | +3.81% |
| +15 days | −0.90% |
| +30 days | −5.91% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202649.24%Promoter
Promoters49.24%12.07
FIIs2.60%1.90
DIIs8.30%4.54
Public39.76%9.42
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Viyash Scientific | ₹218.39 | 43.54 | 9,648 | 0.00% | 79 | +103.59% | 946 | +19.54% | 13.42% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts61
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025PPTNov 2025TranscriptAug 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Oct - We are enclosing herewith the copy of Newspaper Publications for Special Window for Transfer and Dematerialisation of Physical Securities.Announcement under Regulation 30 (LODR)-Change in Management 20 Oct - Dr. Mallikharjuna Rao Nagineni appointed SVP-HR effective October 20, 2026; Prasad Lad retires.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 17 OctAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 8 OctCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.